GlassScriptPhysician profile
Peggy Jo Ostrander
NPI 1972568665
$3,687.18
in general payments reported to CMS, 2019-2025
23 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $647 · 2023: $758 · 2024: $673 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,459.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $479.30 | 2023-2025 | |
| Amgen INC. | $442.31 | 2023-2025 | Krystexxa, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $342.83 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $249.82 | 2021-2025 | Austedo Xr |
| Sumitomo Pharma America, INC. | $186.85 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.44 | 2021-2023 | |
| Abbvie INC. | $172.21 | 2021-2023 | |
| Abbott Laboratories | $153.43 | 2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $124.40 | 2025 | |
| Sk Life Science, INC. | $124.10 | 2024 | Xcopri |
| Astrazeneca Pharmaceuticals LP | $120.16 | 2021 | |
| Grifols USA, LLC | $115.75 | 2025 | Prolastin-C Liquid |
| Alnylam Pharmaceuticals INC. | $107.70 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $106.58 | 2022 | |
| Exeltis, USA INC. | $103.35 | 2025 | Twirla, Slynd |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $100.04 | 2022 | |
| Kyowa Kirin, INC. | $95.72 | 2024 | Crysvita |
| Lilly USA, LLC | $87.39 | 2023 | Mounjaro |
| Novo Nordisk INC | $87.03 | 2022 | |
| Stemline Therapeutics INC. | $83.07 | 2022 | |
| Edwards Lifesciences Corporation | $81.30 | 2022 | |
| Medtronic, INC. | $71.43 | 2022 | |
| Galderma Laboratories, L.P. | $69.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peggy Ostrander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.